PHOENIX NEST INC
Total received in grants · trailing 12 months
$1.5M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
1separate grants, trailing 12 months
PHOENIX NEST INC has received $1.5M across 1 federal grant of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Health and Human Services | MANUFACTURING AND ANALYTICAL DEVELOPMENT FOR JLK-247 GENE THERAPY - PROJECT SUMMARY/ABSTRACT LYSOSOMAL STORAGE DISEASES (LSD) ARE RARE AND ARE AN INHERITED METABOLIC DISORDER CAUSED BY DEFECTS IN THE CELLULAR CATABOLIC SYSTEM. MUCOPOLYSACCHARIDOSIS TYPE IIIC (MPS IIIC OR SANFILIPPO DISEASE TYPE C) IS ONE SUCH LSD THAT IS CAUSED BY DEFICIENCY OF THE ENZYME HEPARAN SULFATE ACETYL COA: -GLUCOSAMINIDE N- ACETYLTRANSFERASE, (HGSNAT) ESSENTIAL FOR DEGRADATION OF HEPARAN SULFATE, A REPEATING CARBOHYDRATE GENERALLY FOUND ATTACHED TO PROTEOGLYCANS. THIS DISEASE CAUSES ACCUMULATION OF HEPARAN SULFATE RESULTING IN PROGRESSIVE AND SEVERE NEUROLOGICAL DETERIORATION EARLY IN LIFE WITH LITTLE SOMATIC FEATURES. THE SYMPTOMS IN PATIENTS WITH MPS IIIC MAY PRESENT AT AN AVERAGE AGE OF 3.5 YEARS OF AGE WITH PSYCHOMOTOR DEVELOPMENTAL DELAYS AND BEHAVIORAL PROBLEMS. BEFORE THE AGE OF 15 YEARS VERBAL COMMUNICATION IS OFTEN LOST IN PATIENTS WITH MPS IIIC. MOST LOSE THE ABILITY TO WALK BETWEEN THE 20 AND 30 YEARS OF AGE. THE CONDITION IS FATAL BY AN AVERAGE AGE OF 34 YEARS (RANGE, 25-48). ENZYME REPLACEMENT THERAPIES ARE NOT AN OPTION SINCE THE PROTEIN IS LOCALIZED AND BOUND TO LYSOSOMAL MEMBRANE. THERE ARE CURRENTLY NO TREATMENTS AVAILABLE FOR MPS IIIC. INDIVIDUALS AFFECTED BY MPS IIIC ARE MANAGED WITH SUPPORTIVE CARE, CONSULTATION WITH MEDICAL PROFESSIONALS FROM MULTIPLE DISCIPLINES, PHYSICAL THERAPY, AND PHARMACOLOGICAL INTERVENTIONS TO ALLEVIATE SYMPTOMS. GENE THERAPY REPRESENTS A REASONABLE AND PROMISING APPROACH TO PROVIDE A MEANINGFUL AND LONG-TERM THERAPEUTIC BENEFIT FOR THIS POPULATION SOON. WE HAD A POSITIVE INTERACTION WITH THE FDA AND RECEIVED GUIDANCE FOR MOVING OUR PROGRAM INTO THE CLINICS. IN PREPARATION FOR THE INTERVENTIONAL STUDY WE NEED TO MANUFACTURE A 500 L CGMP LOT OF JLK-247 GENE THERAPY VECTOR TO TREAT MPS IIIC PATIENTS. THE PRODUCT USED FOR DOSING CLINICAL PATIENTS ON A PHASE I TRIAL IS REQUIRED TO MEET THE CRITICAL QUALITY ATTRIBUTES OF BEING PURE, POTENT AND STERILE. THE PRODUCT UNDERGOES STRINGENT TESTING TO DEMONSTRATE ITS SUITABILITY FOR HUMAN DOSING. THE ANALYTICAL TESTING ITSELF NEEDS TO BE DEVELOPED AND QUALIFIED PRIOR TO THE RELEASE OF MATERIAL FOR DOSING. SUCH STANDARDS REQUIRE A WELL-REGULATED ENVIRONMENT AND THE MANUFACTURING IS ROUTINELY PERFORMED BY CERTIFIED CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO). MOST OF THE WORK PROPOSED IN THIS APPLICATION WILL BE EXECUTED BY CONTRACTED SERVICE PROVIDERS AS A FEE FOR SERVICE. PRODUCING SUFFICIENT JLK-247 BY SCALING UP THE MANUFACTURING WILL PUT US A STEP CLOSER TO TREATING THE PATIENTS SUFFERING FROM THIS TERRIBLE DISEASE. | $1,492,329 |